Serum kallikrein-8 correlates with skin activity, but not psoriatic arthritis, in patients with psoriatic disease

Clinical Chemistry and Laboratory Medicine

Volumn 51, Issue 2, 2013, Pages 317-325

  Eissa, Azza ^a,b   Cretu, Daniela ^a,b   Soosaipillai, Antoninus ^b   Thavaneswaran, Arane ^c   Pellett, Fawnda ^c   Diamandis, Anastasia ^d   Cevikbas, Ferda ^e   Steinhoff, Martin ^e   Diamandis, Eleftherios P ^a,b,d   Gladman, Dafna ^a,c   Chandran, Vinod ^f  

^a UNIVERSITY OF TORONTO   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c TORONTO WESTERN HOSPITAL   (Canada)

^d UNIVERSITY HEALTH NETWORK   (Canada)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF TORONTO   (Canada)

Author keywords

biomarker; ELISA; kallikreins; psoriasis; psoriasis area and severity index (PASI); psoriatic arthritis; screening

Indexed keywords

KALLIKREIN 6; NEUROPSIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; OSTEOARTHRITIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PSORIASIS; PSORIATIC ARTHRITIS; SYNOVIAL FLUID;

BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; DERMATITIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KALLIKREINS; MALE; MIDDLE AGED; PSORIASIS; SEVERITY OF ILLNESS INDEX; SYNOVIAL FLUID;

EID: 84875436532     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2012-0251     Document Type: Article

References (34)

1. Kurd SK, Gelfand JM. The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004. J Am Acad Dermatol 2009;60:218-24.
2. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature 2007;445:866-73.
3. Scarpa R, Altomare G, Marchesoni A, Balato N, Matucci Cerinic M, Lotti T, et al. Psoriatic disease: concepts and implications. J Eur Acad Dermatol Venereol 2010;24:627-30.
4. Nograles KE, Brasington RD, Bowcock AM. New insights into the pathogenesis and genetics of psoriatic arthritis. Nat Clin Pract Rheumatol 2009;5:83-91.
5. Langley RG, Krueger GG, Griffiths CE. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis 2005;64 Suppl 2:ii18-23; discussion ii4-5.
6. Reich K, Kruger K, Mossner R, Augustin M. Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. Br J Dermatol 2009;160:1040-7.
7. Borgono CA, Diamandis EP. The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer 2004;4:876-90.
8. Yousef GM, Diamandis EP. The new human tissue kallikrein gene family: structure, function, and association to disease. Endocr Rev 2001;22:184-204.
9. Brattsand M, Stefansson K, Lundh C, Haasum Y, Egelrud T. A proteolytic cascade of kallikreins in the stratum corneum. J Invest Dermatol 2005;124:198-203.
10. Eissa A, Amodeo V, Smith CR, Diamandis EP. Kallikrein-related peptidase-8 (KLK8) is an active serine protease in human epidermis and sweat and is involved in a skin barrier proteolytic cascade. J Biol Chem 2011;286:687-706.
11. Stefansson K, Brattsand M, Ny A, Glas B, Egelrud T. Kallikreinrelated peptidase 14 may be a major contributor to trypsin-like proteolytic activity in human stratum corneum. Biol Chem 2006;387:761-8.
12. Briot A, Deraison C, Lacroix M, Bonnart C, Robin A, Besson C, et al. Kallikrein 5 induces atopic dermatitis-like lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndrome. J Exp Med 2009;206:1135-47.
13. Caubet C, Jonca N, Brattsand M, Guerrin M, Bernard D, Schmidt R, et al. Degradation of corneodesmosome proteins by two serine proteases of the kallikrein family, SCTE/KLK5/hK5 and SCCE/KLK7/hK7. J Invest Dermatol 2004;122:1235-44.
14. Yamasaki K, Schauber J, Coda A, Lin H, Dorschner RA, Schechter NM, et al. Kallikrein-mediated proteolysis regulates the antimicrobial effects of cathelicidins in skin. Faseb J 2006;20:2068-80.
15. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006;54:2665-73.
16. Gladman DD, Thavaneswaran A, Chandran V, Cook RJ. Do patients with psoriatic arthritis who present early fare better than those presenting later in the disease? Ann Rheum Dis 2011;70:2152-4.
17. Chandran V, Gladman DD. Update on biomarkers in psoriatic arthritis. Curr Rheumatol Rep 2010;12:288-94.
18. Gladman DD. Spondyloarthropathies: Targeted therapy for psoriatic arthritis. Nat Rev Rheumatol 2009;5:241-2.
19. Myers WA, Gottlieb AB, Mease P. Psoriasis and psoriatic arthritis: clinical features and disease mechanisms. Clin Dermatol 2006;24:438-47.
20. Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and therapeutic criteria committee of the American Rheumatism Association. Arthritis Rheum 1986;29; 1039-49.
21. Komatsu N, Saijoh K, Sidiropoulos M, Tsai B, Levesque MA, Elliott MB, et al. Quantification of human tissue kallikreins in the stratum corneum: dependence on age and gender. J Invest Dermatol 2005;125:1182-9.
22. Chandran V, Cook RJ, Edwin J, Shen H, Pellett FJ, Shanmugarajah S, et al. Soluble biomarkers differentiate patients with psoriatic arthritis from those with psoriasis without arthritis. Rheumatology (Oxford) 2010;49:1399-405.
23. Anandarajah AP, Ritchlin CT. The diagnosis and treatment of early psoriatic arthritis. Nat Rev Rheumatol 2009;5:634-41.
24. Borgono CA, Michael IP, Komatsu N, Jayakumar A, Kapadia R, Clayman GL, et al. A potential role for multiple tissue kallikrein serine proteases in epidermal desquamation. J Biol Chem 2007;282:3640-52.
25. Eissa A, Diamandis EP. Human tissue kallikreins as promiscuous modulators of homeostatic skin barrier functions. Biol Chem 2008;389:669-80.
26. Komatsu N, Saijoh K, Kuk C, Shirasaki F, Takehara K, Diamandis EP. Aberrant human tissue kallikrein levels in the stratum corneum and serum of patients with psoriasis: dependence on phenotype, severity and therapy. Br J Dermatol 2007;156: 875-83.
27. Kuwae K, Matsumoto-Miyai K, Yoshida S, Sadayama T, Yoshikawa K, Hosokawa K, et al. Epidermal expression of serine protease, neuropsin (KLK8) in normal and pathological skin samples. Mol Pathol 2002;55:235-41.
28. Rahman MM, Bhoola KD, Elson CJ, Lemon M, Dieppe PA. Identification and functional importance of plasma kallikein in the synovial fluids of patients with rheumatoid, psoriatic, and osteoarthritis. Ann Rheum Dis 1995;54;345-50.
29. Ribbens C, Martin y Porras M, Franchimont N, Kaiser MJ, Jaspar JM, Damas P, et al. Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment. Ann Rheum Dis 2002;61:161-6.
30. Bowcock AM, Shannon W, Du F, Duncan J, Cao K, Aftergut K, et al. Insights into psoriasis and other inflammatory diseases from large-scale gene expression studies. Hum Mol Genet 2001;10:1793-805.
31. Gladman DD, Farewell VT. HLA studies in psoriatic arthritis: current situation and future needs. J Rheumatol 2003;30: 4-6.
32. Slobodin G, Rosner I, Rozenbaum M, Boulman N, Kessel A, Toubi E. Psoriatic arthropathy: where now? Isr Med Assoc J 2009;11:430-4.
33. Veale DJ, Ritchlin C, FitzGerald O. Immunopathology of psoriasis and psoriatic arthritis. Ann Rheum Dis 2005;64(Suppl 2):ii26-9.
34. Weger W. Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents. Br J Pharmacol 2010;160:810-20.